Robert Orenstein, Mayo Clinic, 5777 E Mayo Blvd, Phoenix, AZ 85054, USA. Email:
Nutr Clin Pract. 2013 Oct;28(5):589-98. doi: 10.1177/0884533613497516. Epub 2013 Aug 26.
In recent years, fecal microbiota transplantation (aka fecal transplantation, fecal bacteriotherapy, FMT) has become increasing utilized to treat recurrent and refractory Clostridium difficile infection (CDI). Almost 600,000 cases of CDI occur each year in the United States. Of these, an estimated 15,000 patients have a recurrence. The management of recurrent disease has been challenging for patients and clinicians. Increasingly, FMT has been recognized as an effective option for these patients. This article explores why FMT has reemerged as a practical therapeutic modality. In the process, the logistics by which the procedure is performed and the factors that may affect quality, safety, and patient outcomes will be described.
近年来，粪便微生物群移植（又称粪便移植、粪便细菌治疗、FMT）已越来越多地用于治疗复发性和难治性艰难梭菌感染（CDI）。在美国，每年约有 60 万例 CDI 发生。其中，估计有 15000 名患者复发。复发性疾病的治疗一直是患者和临床医生面临的挑战。越来越多的人认识到 FMT 是这些患者的有效治疗选择。本文探讨了为什么 FMT 重新成为一种实用的治疗方式。在此过程中，将描述该程序的执行方式以及可能影响质量、安全性和患者结果的因素。
